At Inotek your vision is our focus. We’re dedicated to scientific innovation and medical research to find solutions that can protect and potentially restore the vision of those suffering from diseases of the eye. Our groundbreaking innovation in adenosine science has yielded a new approach to glaucoma. Trabodenoson is being developed to address both the control of pressure in the eye, as well as the retinal damage that ultimately leads to vision loss. We are committed to achieving this with a much-improved side effect profile relative to existing therapies.
- Inotek Pharmaceuticals Corporation Announces Closing of $79.2 Million Public Offering Including Exercise in Full of Underwriters' Option to Purchase Additional Shares Read Full Press Release
- Inotek Pharmaceuticals Corporation Announces Pricing of $68.9 Million Public Offering Read Full Press Release
- Inotek Pharmaceuticals Corporation Reports Second Quarter 2015 Financial Results and Operational Highlights Read Full Press Release
- Inotek Pharmaceuticals Phase 3 Development Plan Conference Call Webcast Visit the Webcast Archive